Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company combining therapeutic development with a revenue-generating contract development and manufacturing organization (“CDMO”), reported first-half 2026 revenue of $949,000, up from $773,000 in the prior-year period, while committed customer orders reached approximately $3.1 million as of Aug. 16, 2026, including approximately $2.1 million already invoiced. The company is also advancing an expanded clinical manufacturing and chemistry, manufacturing and controls (“CMC”) program for a U.S.-based biopharmaceutical company, with approximately $650,000 in cash payments and advances received and substantive activities underway while a definitive agreement remains under negotiation. The program is intended to support an investigational drug product toward a U.S. investigational new drug (“IND”) submission and Phase III clinical development. Scinai continues to pursue approximately $5 million in CDMO revenue for 2026.
Scinai reported an operating loss of approximately $4.6 million for the first half, compared with $3.8 million a year earlier, while net income was approximately $1.6 million versus a net loss of approximately $4.1 million, primarily reflecting a $6.4 million bargain purchase gain associated with the acquisition of Recipharm Israel. Cash, cash equivalents and restricted cash totaled approximately $2.9 million as of June 30, 2026. The company continues to advance its PC111 and NanoAbs therapeutic programs and will host an investor webinar Aug. 26, 2026, to discuss recent developments, financial performance and upcoming milestones.
To view the full press release, visit https://nnw.fm/Be7Ky
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://nnw.fm/SCNI
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer